The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin

Clinical and Experimental Dermatology, Supplement

Volumn 28, Issue 1, 2003, Pages 33-35

  Giannotti, B ^a   Vanzi, L ^a   Difonzo, E M ^a   Pimpinelli, N ^a  

^a Dipartimento Scienze Dermatologiche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; KERATOLYTIC AGENT; ENDONUCLEASE; ENDONUCLEASE V; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BASAL CELL CARCINOMA; CANCER LOCALIZATION; CASE REPORT; DISEASE ASSOCIATION; ERYTHEMA; FOLLOW UP; HUMAN; MALE; MELANOMA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RARE DISEASE; SCAR FORMATION; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURGICAL RISK; TREATMENT INDICATION; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM; DRUG COMBINATION; FACE TUMOR; ORAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; ANAMNESIS; CANCER SURGERY; CRYOTHERAPY; PHOTOSENSITIVITY DISORDER; VERRUCA VULGARIS;

ACITRETIN; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADOLESCENT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG THERAPY, COMBINATION; FACIAL NEOPLASMS; HUMANS; KERATOLYTIC AGENTS; MALE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM;

EID: 1542644920     PISSN: 09663487     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.28.s1.11.x     Document Type: Article

References (21)

1. Stary A, Sarasin A. The genetics of the hereditary xeroderma pigmentosum syndrome. Biochimie 2002; 84: 49-60.
2. Moriwaki S, Kraemer KH. Xeroderma pigmentosum-bridging a gap between clinic and laboratory. Photodermatol Photoimmunol Photomed 2001; 17: 47-54.
3. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, occular and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241-50.
4. Drake MLA, Ceilley RI, Cornelison RL et al. Guidelines of care for basal cell carcinoma. J Am Acad Dermatol 1992; 26: 117-20.
5. Kopera D, Cerroni L, Fink-Puches R, Kerl H. Different treatment modalities for the managment of a patient with the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1996; 345: 937-9.
6. Hamouda B, Jamila Z, Najet R et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol 2001; 44: 1054.
7. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25-30.
8. Hengge UR, Esser S, Schultewolter T et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143: 1026-31.
9. Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002; 46: 545-8.
10. Beutner KR, Spruance SL, Hougham AJ et al. Therapeutic response of basal carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
11. Cleaver JE. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci 2000; 23: 1-11.
12. Stary A, Sarasin A. The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes. Cancer Survey 1996; 26: 155-71.
13. Lacour JP. Carcinogenesis of basal cell carcinoma: genetics and molecular mechanisms. Br J Dermatol 2002; 146 (Suppl.): 17-9.
14. D'Errico M, Calcagnile A, Canzona F et al. UV mutation signature in tumour suppressor genes involvled in skin carcinogenesis in xeroderma pigmentosum patients. Oncogene 2000; 19: 463-7.
15. Somos S, Farkas B, Schneider I. Cancer protection in xeroderma pigmentosum variant (VP-V). Anticancer Res 1999; 19: 2195-9.
16. Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Curr Treat Options Oncol 2002; 3: 193-203.
17. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma pigmentosum Study Group. Lancet 2001; 357: 926-9.
18. Tyring SK, Arany I, Stanley MA et al. A randomised, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178: 551-5.
19. Strauss RM, Doyle EL, Mohsem AH, Green ST. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001; 12: 264-6.
20. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicentre 6 week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
21. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26: 577-8.